Categories: News

BBS-Bioactive Bone Substitutes Plc: Correction to the release of BBS-Bioactive Bone Substitutes Plc published on 21.12.2020 at 16:30 CET

The release of BBS-Bioactive Bone Substitutes’ financial calendar and Annual General Meeting in 2021 published by BBS-Bioactive Bone Substitutes Plc on 21.12.2020 at 16:30 CET has been corrected. A clause in accordance with the Market Abuse Regulation has been removed from the release. The corrected release is in entirety below.

BBS-Bioactive Bone Substitutes’ financial calendar and Annual General Meeting in 2021

During the year 2021, BBS-Bioactive Bone Substitutes Plc (”BBS”) will publish the financial information as follows: 

Financial Statements Release for the year 2020               Wed, 24 February 2021  

Half-year financial report January-June 2021                   Wed, 25 August 2021        

The Annual Report for the year 2020 will be published on the week 13/2021. 

The Annual General Meeting is planned to be held on Wednesday, 28 April 2021. The Board of Directors of BBS Plc will convene the meeting at a later date.  

More information:
Ilkka Kangasniemi, CEO
tel. +358 40 7080 307
e-mail: ilkka.kangasniemi@bbs-artebone.fi

Distribution:
Nasdaq Helsinki Oy
Nasdaq Stockholm AB
Main Media
www.bbs-artebone.fi

BBS – Bioactive Bone Substitutes Ltd

BBS-Bioactive Bone Substitutes Plc is a Finnish orthobiologic biotech company. We have developed a new product for healing of difficult bone fractures and for solving the problems in bone healing. Our mission is to offer new generation medicinal products for the orthopedic surgery. The research and development in the field of medicine requires perseverance and courage to develop new things.  We have over 20 years of expertise in this. Our operations are characterised by top expertise, innovativeness and dedicated and committed employees. The first product, ARTEBONE® paste, is ready and the application process for the CE-marking enabling commercialization is in progress.

More information: www.bbs-artebone.fi.

BBS-Bioactive Bone Substitutes Plc shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. The company’s Certified Adviser is Stockholm Certified Advisers AB, p. +46 70 5516 729, info@certifiedadviser.se

Staff

Recent Posts

HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results

First Patients Enrolled in Pivotal Study Evaluating AIMIGo™ System for Synthesizing a 12-Lead ECG Ongoing…

7 hours ago

Delivra Health Brands Announces Adoption of a New Fixed Share Option Plan

Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - Delivra Health Brands Inc. (TSXV: DHB)…

7 hours ago

Avinger Reports Fourth Quarter and Full Year 2023 Results

New Strategic Partnership Provides Funding to Support U.S. Growth Initiatives and Coronary Product Development, Opens…

7 hours ago

Music’s Healing Influence on Our Physiology

Pioneering the Path of Sound Therapy with Biofield TuningBURLINGTON, VERMONT / ACCESSWIRE / March 20,…

10 hours ago

NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering

ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or…

10 hours ago

Mending Kids’ Imagine Gala Triumphs, Elevating Children’s Surgical Care Initiatives

LOS ANGELES, CA / ACCESSWIRE / March 20, 2024 / The Skirball Cultural Center was…

10 hours ago